Trevi Therapeutics (TRVI) Return on Capital Employed (2019 - 2026)
Trevi Therapeutics' quarterly Return on Capital Employed came in at 28.47% in Q1 2026, up 2048.0% year-on-year from 1.33% in Q1 2025, and down 10.21% quarter-over-quarter from 25.83% in Q4 2025.
Trevi Therapeutics has reported Return on Capital Employed for 8 years, with the latest figure at 28.47% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2048.0% year-over-year to 28.47%; the trailing twelve-month figure through Mar 2026 stood at 28.47% (up 2048.0% YoY), and the FY2025 full-year result was 34.64%, up 2284.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 28.47%, down from 25.83% in the prior quarter.
- The five-year high for Return on Capital Employed was 25.79% in Q3 2025, with the low at 145.67% in Q1 2022.
- Average Return on Capital Employed over 5 years is 48.77%, with a median of 34.93% recorded in 2022.
- Peak annual rise in Return on Capital Employed reached 11892 bps in 2022, while the deepest fall reached 6514 bps in 2022.
- Tracing TRVI's Return on Capital Employed over 5 years: stood at 26.63% in 2022, then sank by 47 bps to 39.07% in 2023, then plunged by 66 bps to 64.9% in 2024, then soared by 60 bps to 25.83% in 2025, then fell by 10 bps to 28.47% in 2026.
- The last three Return on Capital Employed figures came in at 28.47% (Q1 2026), 25.83% (Q4 2025), and 25.79% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | -28.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.47% |
| Dec 31, 2025 | -25.83% |
| Sep 30, 2025 | -25.79% |
| Jun 30, 2025 | -33.96% |
| Mar 31, 2025 | -48.95% |
| Dec 31, 2024 | -64.90% |
| Sep 30, 2024 | -77.47% |
| Jun 30, 2024 | -62.18% |
| Mar 31, 2024 | -48.62% |
| Dec 31, 2023 | -39.07% |
| Sep 30, 2023 | -33.93% |
| Jun 30, 2023 | -29.85% |
| Mar 31, 2023 | -28.61% |
| Dec 31, 2022 | -26.63% |
| Sep 30, 2022 | -34.93% |
| Jun 30, 2022 | -74.30% |
| Mar 31, 2022 | -145.67% |
| Dec 31, 2021 | -145.56% |
| Sep 30, 2021 | -131.17% |
| Jun 30, 2021 | -106.64% |
| Mar 31, 2021 | -80.53% |
| Dec 31, 2020 | -70.71% |
| Sep 30, 2020 | -66.30% |
| Jun 30, 2020 | -69.48% |
| Mar 31, 2020 | -61.05% |
| Dec 31, 2019 | -46.09% |
| Sep 30, 2019 | -39.38% |
| Jun 30, 2019 | -59.20% |
| Mar 31, 2019 | -197.03% |